Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI) 2Q26 Ready to Announce with Confidence?
Dallas, Texas--(Newsfile Corp. - August 13, 2026) - NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI). Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI). 2Q26 meaningfully improves the clinical setup for NTHI, with NEO100 delivering a positive Phase 2a readout and NEO212 gaining regulatory clarity. NEO100 met its primary endpoint with six-month PFS of 48.9% by RANO 2.0 using Kaplan-Meier estimation versus a pre-specified 20% benchmark (p=0.0047), while median OS reached 26.09 months and no major toxicities were reported. We view the survival signal as the more important read through, with management citing 6-9 months for current salvage therapy in recurrent brain cancer, although confirmation in a randomized study remains the next test. The readout moves NEO100 into a potential registrational program, with the Company intending to request a Type B FDA meeting. Financial results are secondary, with R&D increasing to $2.6M vs. $0.7M y/y.
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
NEO100's Phase 2a readout materially strengthens the lead program, with PFS-6 of 48.9% versus the 20% benchmark and median OS of 26.09 months. The favorable tolerability profile and lack of major toxicities further support the potential for chronic, patient-friendly treatment and move NEO100 toward a registrational-stage opportunity.
FDA alignment is now the key near-term catalyst, with NeOnc planning a Type B meeting to determine NEO100's registrational trial design, endpoints and potential approval pathway. NEO212 also gained regulatory momentum through Phase 2 CMC clearance and FDA feedback indicating a potential accelerated approval pathway.
The investment case is broadening beyond a single trial or asset, with NEO100 extending into meningioma and pediatric brain tumors while NEO212 provides a differentiated second clinical program. This platform breadth increases longer-term optionality, although funding remains important as development activity expands.
Click image above to view full announcement.
About Stonegate
Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies.
Contacts:
Stonegate Capital Partners
(214) 987-4121
info@stonegateinc.com
Source: Stonegate, Inc.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/309582
Source: Stonegate, Inc.
Analyst, journalist, or company stakeholder? Sign up to receive news releases by email for Stonegate, Inc. or all companies in the Investment Banking industry.
Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI) 2Q26
2026-08-13 4:18 PM EDT
Stonegate Updates Coverage on SES AI Corp. (SES) 2Q26
2026-08-12 7:34 PM EDT
Stonegate Capital Partners Updates Coverage on NU Skin Enterprises Inc. (NUS) 2Q26
2026-08-11 4:24 PM EDT
May 27, 2026
Disclosure Intelligence Series How disclosure works in modern capital markets A May 2026 TMX Newsfile analysis found that mining and energy press releases generated higher levels of AI activity per release than Technology & Innovation announcements. The study analyzed AI crawler activity across approximately 220 press releases distributed through TMX Newsfile’s network over a 72-hour period. Results showed that AI systems are actively processing mining and energy press releases at scale. AI...
Investment Banking